Scheduling changes offer “liberty” to all
March 20, 2024
HEALTHCARE discussions at APP2024 last week focused on the role of pharmacists in medication management, and how down-scheduling of medicines gives pharmacists the "liberty" to offer early intervention to patients for distressing conditions such as allergic rhinitis and migraines.
Bringing relief to around 4.5 million sufferers of the condition, Dymista Allergy is the combination allergy treatment currently available in Australia without prescription due to the TGA's down scheduling of the product last year.
Manufacturer of the product and APP program sponsor, Viatris Australia's Country Manager Sylvain Vigneault (pictured) shared insights with Pharmacy Daily that navigating the healthcare system for hayfever patients can be complex, often involving referrals from general practitioners to specialists.
"A proper conversation around the disease and the ability to provide medication immediately is extremely important in bringing the condition under control," Vigneault remarked, highlighting the significance of empowering pharmacists in patient care.
He also discussed how the availability of over-the-counter medicines granted pharmacists the "liberty to engage in meaningful discussions with patients", and recommend appropriate treatments to their patients.
This shift reflects a broader conversation around the scope of practice in healthcare, demonstrating that effective patient care extends beyond prescription-based products, Vigneault said.
"We believe in bridging the gap between accessibility and quality healthcare," he stated, emphasising the company's commitment to patient-centric approaches.
Moreover, Vigneault delved into the process of down-scheduling medications, citing the example of the company's antimigraine product Relpax, now also accessible without a prescription.
This move toward increased accessibility aligns with efforts to streamline overall healthcare delivery and ensure timely access to essential medications.
Another crucial aspect addressed was the importance of local manufacturing in ensuring medication availability.
Vigneault stressed the need to capitalise on locally produced products to mitigate supply chain challenges, particularly in light of recent global disruptions such as the COVID-19 pandemic and logistical constraints.
"Local manufacturing not only strengthens supply chains but also fosters economic resilience," Vigneault remarked, underlining the significance of domestic production in safeguarding medication access.
In conclusion, Vigneault's insights underscored the evolving dynamics of healthcare delivery, emphasising the need for collaboration, innovation, and a patient-centric approach. JG
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Mar 24To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Mar 24
